CCM
EBS icon

Cullen Capital Management’s Emergent Biosolutions EBS Stock Holding History

Cullen Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,708
Closed -$246K – 211
2022
Q3 		$246K Buy
+11,708
New +$326K ﹤0.01% 253

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cullen Capital Management's EBS Position: Q4 2022 in Review

Cullen Capital Management sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 11,708 shares — an estimated $246K sold.

Cullen Capital Management first reported a position in EBS in Q3 2022 and held it in 1 quarter. The position peaked at $246K in Q3 2022. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Cullen Capital Management reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Cullen Capital Management sold 11,708 Emergent Biosolutions shares in Q4 2022, an estimated $246K.
  • Cullen Capital Management first reported a position in Emergent Biosolutions in Q3 2022 and held it in 1 quarter.
  • Cullen Capital Management's Emergent Biosolutions position peaked at $246K in Q3 2022.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Cullen Capital Management's 13F filing for Q4 2022, filed 16 Feb 2023.